HIV / AIDS in the News

Navigating the GLP-1 Surge and HIV Care: Todd Brown, MD, PhD - AJMC

 

Feb. 25: HIV awareness, gaming update, and UNLV Dance - KNPR

 

New PAHO course strengthens health workers’ capacity to deliver oral and long-acting PrEP to reduce HIV infections - Pan American Health Organization (PAHO)

 

Merck Reshapes Leadership As HIV And RSV Prospects Take Center Stage - Yahoo Finance

 

State ducks legal challenge, enacts emergency rule to cut HIV/AIDS medication assistance funding - WUSF

 

How Philly hopes to continue decline in new HIV infections - Billy Penn at WHYY

 

The Fountain of Youth: Groundbreaking study at UofR investigates if HIV drug could extend healthy aging - WHEC.com

 

UR study to test HIV drug’s impact on aging - RochesterFirst

 

UR study to test HIV drug’s impact on aging - RochesterFirst

 

Gilead, Merck & Co. showcase their once-daily, oral options for HIV - FirstWord Pharma

 

Phase III Data Support Single-Tablet HIV-1 Therapy for Older Adults with Resistant Infection - Inside Precision Medicine

 

Gilead, Merck plan to debut new daily HIV pills - Endpoints News

 

Florida HIV medication program faces eligibility cuts this weekend - WCTV

 

Florida uses emergency rule to cut patients off AIDS medication - The Detroit News

 

Pocan Introduces Resolution Recognizing “HIV Is Not a Crime Awareness Day” - Urban Milwaukee

 

State ducks legal challenge, enacts emergency rule to cut HIV/AIDS medication assistance funding - WLRN

 

Pharmacists may soon prescribe HIV prevention drugs - FOX 5 Atlanta

 

Gilead's experimental HIV treatment shows low discontinuation rates in studies - Reuters

 

ViiV Healthcare presents pipeline data for two investigational HIV treatment therapies with potential for twice-yearly dosing - GSK

 

Switching to Bictegravir-Lenacapavir Combination Maintains HIV Virologic Suppression in Complex Regimen Patients - Contagion Live

 

what happens if Ryan White ends for HIV AIDS - Infectious Disease Special Edition

 

ViiV Healthcare presents pipeline data for two investigational HIV treatment therapies with potential for twice-yearly dosing - Business Wire

 

ViiV Healthcare reports positive 12-month data showing investigational bNAb lotivibart (N6LS) maintains high levels of viral suppression in long-acting HIV treatment regimen - Business Wire

 

Pritelivir Demonstrates Superior Efficacy in People Living with HIV with Refractory HSV in Phase 3 PRIOH-1 - Yahoo Finance

 

Gilead paints clearer picture of next-gen HIV tablet's prowess with results from 2 late-stage studies - Fierce Pharma

 

Single daily pill shows promise as replacement for complex, multi-tablet HIV treatment regimens - Medical Xpress

 

New single-pill HIV therapy promises boost for long-term virus survivors - Financial Times

 

A single once-daily pill combining two antiretrovirals simplifies HIV treatment, as demonstrated by a phase 3 trial - Science Media Centre España

 

Merck (MRK) Reveals Positive Phase 3 Trial Results for HIV-1 Tre - GuruFocus

 

US funding freeze linked to HIV care disruptions in 32 countries, study finds - Medical Xpress